Microfluidic hemophilia models using blood from healthy donors
Abstract Background Microfluidic clotting assays permit drug action studies for hemophilia therapeutics under flow. However, limited availability of patient samples and Inter‐donor variability limit the application of such assays, especially with many patients on prophylaxis. Objective To develop ap...
Guardado en:
Autores principales: | Xinren Yu, Karen A. Panckeri, Lacramioara Ivanciu, Rodney M. Camire, Carmen H. Coxon, Adam Cuker, Scott L. Diamond |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/71da544d77aa43e085358a8ca40dc390 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Haowei (Linda) Sun, et al.
Publicado: (2021) -
Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Jennifer Stimec, et al.
Publicado: (2021) -
COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
por: Can Alp GENÇ, et al.
Publicado: (2021) -
Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
por: Samuel sarmiento Doncel, et al.
Publicado: (2021) -
External qualification of the Web‐Accessible Population Pharmacokinetic Service–Hemophilia (WAPPS‐Hemo) models for octocog alfa using real patient data
por: Pierre Chelle, et al.
Publicado: (2021)